>ANDS – Between ANA 380 for HBV and ANA 975 for HCV, I don't know how IDIX can effectively compete, especially in the HCV space against other competitors. Their HBV drug already faces challengers.<
You sound confused about the HBV market. Telbivudine is undergoing regulatory review right now in the U.S. and all major countries (the FDA PDUFA date is in October), while ANDS’ ANA 380 just finished dose-ranging studies and hasn’t even started phase-2b yet.
In HCV, ANDS is trying to replace interferon. Even if they succeed at doing that, a polymerase inhibitor, a protease inhibitor, or both, will almost certainly be needed to round out a treatment cocktail. IDIX has the most advanced polymerase inhibitor.
The competitors IDIX is most concerned about are BMY and GILD in the HBV arena, and Roche in the HCV arena. At this point, ANDS is not even on IDIX’s radar screen.
Market Data 
Markets 
AI
